

**THE STRATEGIC COLLABORATION AGREEMENT AND THE PLACEMENT OF 30,000,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY (THE "PLACEMENT SHARES") AT S\$0.50 FOR EACH PLACEMENT SHARE (THE "PLACEMENT")**

**- COMPLETION OF THE PLACEMENT OF THE PLACEMENT SHARES**

---

**1. INTRODUCTION**

The Board of Directors (the "**Board**") of Singapore Medical Group Limited (the "**Company**") refers to the following announcements of the Company:

- (i) the announcement dated 17 February 2017 in relation to, *inter alia*, the proposed issuance of Placement Shares pursuant to a Placement Agreement entered into with CHA Healthcare Co. Ltd. ("**CHC**");
- (ii) the announcement dated 6 March 2017 in relation to the receipt of the listing and quotation notice of the Placement Shares from the SGX-ST for the listing and quotation of the Placement Shares on the Catalist, subject to SGX-ST listing requirements; and
- (iii) the announcement dated 13 March 2017 whereby the parties agreed that CHC shall be substituted with CHA Healthcare Singapore Pte. Ltd. ("**CHS**") as a party to and in the Placement Agreement,

(collectively, the "**Earlier Announcements**").

*Capitalised terms not defined herein shall bear the same meanings ascribed to them in the Earlier Announcements.*

**2. COMPLETION OF THE PLACEMENT**

Further to the Earlier Announcements, the Board is pleased to announce the completion of the Placement ("**Completion**") on 15 March 2017, pursuant to which the 30,000,000 Placement Shares were allotted and issued to CHS in accordance with the terms of the Placement Agreement and the Novation Agreement.

Following Completion,

- (a) the total issued share capital of the Company has increased from 392,143,092 Shares to 422,143,092 Shares, being the enlarged issued and paid-up share capital after the issue and allotment of the Placement Shares; and
- (b) the Placement Shares will rank *pari passu* with and shall carry all rights similar to the existing Shares.

**On Behalf of the Board**

Beng Teck Liang  
Executive Director and Chief Executive Officer

15 March 2017

*This Announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**"), for compliance with the Catalist Rules. The Sponsor has not independently verified the contents of this Announcement.*

*This Announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this Announcement, including the correctness of any of the statements or opinions made or reports contained in this Announcement.*

*The contact person for the Sponsor is Mr Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place #09-01, Singapore Land Tower, Singapore 048623, Telephone: +65 6337 5115.*